New drug TISA-818 shows promise for ARDS in early trial

NCT ID NCT07319351

Completed Disease control Sponsor: EnliTISA (Shanghai) Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II study tested an injectable drug called TISA-818-Inj in 57 adults with acute respiratory distress syndrome (ARDS), a severe lung condition. Participants received either a low dose, a high dose, or a placebo for 14 days. The main goal was to check safety, with secondary goals looking at how long patients needed breathing support. Results may help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TISA-818-Inj (an injectable drug)
What this could lead to: If successful, this could point toward a new treatment option for ARDS, potentially reducing time on ventilators and improving survival.
What could go wrong: This is a small, early-phase trial (57 patients) focused on safety, so results may not confirm effectiveness. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Contacts and locations

Locations

China-Japan Friendship Hospital

Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.